Table 2.
MTAP Expression | |||||
---|---|---|---|---|---|
Total | (%) | Negative (%) | Positive (%) | p-Value | |
Gender (N = 491) Male |
300 | (61.1) | 141 (47.0) | 159 (53.0) | 0.503 |
Female | 191 | (38.9) | 83 (43.5) | 108 (56.5) | |
Age group (N = 504) | |||||
0–19 | 49 | (9.7) | 26 (53.1) | 23 (46.9) | 0.479 |
20–59 | 256 | (50.8) | 112 (43.8) | 144 (56.2) | |
>59 | 199 | (39.5) | 92 (46.2) | 107 (53.8) | |
Location (N = 210) | |||||
Frontal Lobe | 88 | (41.9) | 24 (27.3) | 64 (72.7) | 0.013 |
Parietal Lobe | 41 | (19.5) | 9 (22.0) | 32 (78.0) | |
Temporal Lobe | 66 | (31.4) | 28 (42.4) | 38 (57.6) | |
Occipital Lobe | 10 | (4.8) | 5 (50.0) | 5 (50.0) | |
Cerebellum | 5 | (2.4) | 4 (80.0) | 1 (20.0) | |
KPS (N = 168) | |||||
<70 | 75 | (44.6) | 11 (14.7) | 64 (85.3) | 0.539 |
>70 | 93 | (55.4) | 18 (19.4) | 75 (80.6) | |
Grade (N = 507) | |||||
Low Grade | 18 | (3.6) | 5 (27.8) | 13 (72.2) | 0.149 |
High Grade | 489 | (96.4) | 228 (46.6) | 261 (53.4) | |
Histologic Subtype (N = 507) | |||||
DA (WHO Grade II, NOS) | 18 | (3.6) | 5 (27.8) | 13 (72.2) | 0.272 |
AA (WHO Grade III, NOS) | 24 | (4.7) | 12 (50.0) | 12 (50.0) | |
Ped. GBM (WHO Grade IV, NOS) | 42 | (8.3) | 23 (54.8) | 19 (45.2) | |
Ad. GBM (WHO Grade IV, NOS) | 423 | (83.4) | 193 (45.6) | 230 (54.4) | |
GBM status mutation (N = 460) | |||||
IDH1 mutation (N = 229) | |||||
No | 220 | (96.1) | 117 (53.2) | 103 (46.8) | 0.185 |
Yes | 9 | (3.9) | 7 (77.8) | 2 (22.2) | |
TERT promoter mutation (N = 45) | |||||
No | 11 | (24.4) | 3 (27.3) | 8 (72.7) | 0.687 |
Yes | 34 | (75.6) | 7 (20.6) | 27 (79.4) | |
MGMT promoter methylation (N = 186) | |||||
No | 120 | (64.5) | 75 (62.5) | 45 (37.5) | 0.753 |
Yes | 66 | (35.5) | 39 (59.1) | 27 (40.9) |
Abbreviation: DA: diffuse astrocytoma, AA: anaplastic astrocytoma, Ped. GBM: pediatric glioblastoma, Ad. GBM: adult glioblastoma KPS: Karnofsky Performance Status, NOS: not otherwise specified. T-test (p < 0.05).